POLB 001 patent portfolio strengthened through granting of US patent
POLB 001 patent portfolio strengthened through granting of US patent
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Early data readout indicates a successful LPS human challenge trial
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
POLB 001 LPS human challenge clinical trial successfully completed
CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023
17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it
Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund
Artificial intelligence programme yields multiple novel RSV drug targets